Cambridge Investment Research Advisors Inc. Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Cambridge Investment Research Advisors Inc. lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 478,687 shares of the company’s stock after purchasing an additional 39,584 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Johnson & Johnson were worth $79,385,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Tallon Kerry Patrick purchased a new stake in Johnson & Johnson in the fourth quarter valued at $290,000. Capital & Planning LLC lifted its position in Johnson & Johnson by 13.6% in the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock valued at $221,000 after acquiring an additional 183 shares during the last quarter. Brighton Jones LLC lifted its position in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares during the last quarter. Union Bancaire Privee UBP SA purchased a new stake in Johnson & Johnson in the fourth quarter valued at $85,886,000. Finally, Hudson Value Partners LLC lifted its position in Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company’s stock valued at $5,648,000 after acquiring an additional 1,022 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 1.0%

Shares of Johnson & Johnson stock opened at $151.33 on Tuesday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The company’s 50-day simple moving average is $154.01 and its 200-day simple moving average is $153.69. The firm has a market cap of $364.11 billion, a price-to-earnings ratio of 16.83, a price-to-earnings-growth ratio of 2.27 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.44%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is presently 57.84%.

Analyst Ratings Changes

JNJ has been the subject of a number of research reports. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 16th. Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Royal Bank Of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday, June 5th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Finally, Leerink Partners lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.